- Tytuł:
- LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study
- Autorzy:
- Źródło:
- In Immuno-Oncology and Technology December 2023 20 Supplement
Czasopismo naukowe